Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yi-Hsiang Huang

Showing results (1-10 of 469) with videos related to

Pageof 47
Sort By:
Journal of the Chinese Medical Association : JCMA|June 23, 2009
2009 novel H1N1 influenza: the impact of viral genomic reassortment on immune evasion and vaccine strategyYi-Hsiang Huang
Expert Review of Anti-Infective Therapy|March 12, 2019
Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agentsLai Wei, Yi-Hsiang Huang
Alimentary Pharmacology & Therapeutics|January 8, 2025
Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution-Authors' ReplyYi-Ping Hung, Yi-Hsiang Huang
Journal of the Chinese Medical Association : JCMA|August 7, 2019
To chew carefully and swallow slowlyKuei-Chuan Lee, Yi-Hsiang Huang
Journal of Gastroenterology|April 20, 2026
Optimal treatment selection for hepatocellular carcinoma in the era of immunotherapyChen-Ta Chi, Yi-Hsiang Huang
Journal of the Chinese Medical Association : JCMA|May 4, 2017
Predictors of response to antiviral treatment for chronic hepatitis BYi-Hsiang Huang, Shou-Dong Lee
Hepatology (Baltimore, Md.)|July 29, 2025
Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?Pei-Chang Lee, Yi-Hsiang Huang
Hepatology (Baltimore, Md.)|February 22, 2005
Staging for hepatocellular carcinoma: treatment strategy mattersTeh-Ia Huo, Yi-Hsiang Huang
Journal of Hepatology|November 10, 2024
Reply to: "Immune checkpoint inhibitor therapy for functional cure of hepatitis B in cancer patients: A promising strategy?" and "Patients with HCC as an ideal study population to assess immune checkpoint inhibitors in hepatitis B"Hsien-Chen Mon, Yi-Hsiang Huang
Liver International : Official Journal of the International Association for the Study of the Liver|August 13, 2013
The role of mTOR inhibitors in the treatment of hepatocellular carcinomaYi-Hsiang Huang, Han-Chieh Lin
Pageof 47

Showing results (1-10 of 469) with videos related to

Sort By:
Pageof 47
Journal of the Chinese Medical Association : JCMA|June 23, 2009
2009 novel H1N1 influenza: the impact of viral genomic reassortment on immune evasion and vaccine strategyYi-Hsiang Huang
Expert Review of Anti-Infective Therapy|March 12, 2019
Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agentsLai Wei, Yi-Hsiang Huang
Alimentary Pharmacology & Therapeutics|January 8, 2025
Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution-Authors' ReplyYi-Ping Hung, Yi-Hsiang Huang
Journal of the Chinese Medical Association : JCMA|August 7, 2019
To chew carefully and swallow slowlyKuei-Chuan Lee, Yi-Hsiang Huang
Journal of Gastroenterology|April 20, 2026
Optimal treatment selection for hepatocellular carcinoma in the era of immunotherapyChen-Ta Chi, Yi-Hsiang Huang
Journal of the Chinese Medical Association : JCMA|May 4, 2017
Predictors of response to antiviral treatment for chronic hepatitis BYi-Hsiang Huang, Shou-Dong Lee
Hepatology (Baltimore, Md.)|July 29, 2025
Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?Pei-Chang Lee, Yi-Hsiang Huang
Hepatology (Baltimore, Md.)|February 22, 2005
Staging for hepatocellular carcinoma: treatment strategy mattersTeh-Ia Huo, Yi-Hsiang Huang
Journal of Hepatology|November 10, 2024
Reply to: "Immune checkpoint inhibitor therapy for functional cure of hepatitis B in cancer patients: A promising strategy?" and "Patients with HCC as an ideal study population to assess immune checkpoint inhibitors in hepatitis B"Hsien-Chen Mon, Yi-Hsiang Huang
Liver International : Official Journal of the International Association for the Study of the Liver|August 13, 2013
The role of mTOR inhibitors in the treatment of hepatocellular carcinomaYi-Hsiang Huang, Han-Chieh Lin
Pageof 47